We read with great interest the report by Patnaik et al.
1 stating that the monosomal karyotype in myelodysplastic syndromes (MDS), with or without monosomy 7 or 5, is prognostically worse than other complex karyotypes. Monosomal karyotype (MK) has been defined by Breems et al. 2 in acute myeloid leukemia (AML) as the presence of at least two autosomal monosomies or of a single monosomy associated to at least one structural abnormality. 3 In the report by Patnaik et al. in MDS, 83% of complex karyotypes (defined according to the international prognostic scoring system (IPSS) criteria as the presence of three or more independent chromosomal aberrations) were monosomal, and those patients had indeed poorer prognosis, in terms of overall (OS) and progression-free survival, than other MDS with complex karyotype. Presence of monosomy 5 (À5) or 7 (À7) did not add further prognostic value to MK; del 5q and del 7q were not considered in that analysis.
In this IPSS classification, complex karyotypes are grouped with non-complex chromosome 7 aberrations in the 'poor-risk' cytogenetic category. Most patients with poor-risk cytogenetics are classified as higher risk (IPSS intermediate-2 or high) patients. Hypomethylating agents are active in those patients. 4, 5 In particular, azacitidine (AZA) has demonstrated a survival benefit over conventional care regimens in higher risk MDS (including AML with 20-30% blasts) 6 and has become the standard of care in those patients (at least for those not eligible for allogeneic stem cell transplantation). Studies of MK in AML have been conducted in patients receiving intensive chemotherapy.
2,3 The MDS study of Patnaik et al. 1 included patients analyzed between 1990 and 2010, and thus probably only a fraction of those patients had received hypomethylating agents. We thought useful to review the prognostic value of MK in higher risk MDS treated with AZA.
Between September 2004 and January 2009, before the approval of this drug in Europe, we enrolled 282 higher risk MDS patients in a compassionate patient named program ('Autorisation Temporaire d'Utilisation' program) of AZA. 7 In that cohort, IPSS cytogenetic classification had strong and independent prognostic value for OS, with an especially adverse outcome in patients with IPSS poor-risk karyotype. However, patients with non-complex del 7q/À7 had better OS than those with complex karyotype. 7 We therefore analyzed the impact of MK in the 133 patients with poor-risk cytogenetics in that cohort, including 103 (77%) with complex karyotype (median 6 anomalies), 25 (19%) with non-complex del 7q/À7, and 5 (4%) del 7q/À7 identified by fluorescence in situ hybridization in patients with cytogenetic failure. Of the 103 patients with complex karyotype, 75 (73%) had MK.
1-3 The remaining 28 did not fulfill MK criteria (non-MK). This proportion was close to that reported by Patnaik et al.
1 (83%). In all, 50 (67%) of the 75 monosomal karyotypes included monosomy 7 (n ¼ 26), monosomy 5 (n ¼ 10) or both (n ¼ 14). MK and non-MK patients had comparable baseline characteristics (for age, bone marrow and circulating blast percentages, IPSS, red blood cell transfusion dependency and performance status, all P40.2); 71% of MK and 82% of non-MK cases received a full-dose AZA schedule (75 mg/m 2 /day, 7 days every 4 weeks; P ¼ 0.32). The remaining patients generally received a 5-day schedule, and the median number of cycles was four in both the groups (range 1-19, P ¼ 0.22). The proportion of therapy-related MDS was 35/75 (47%) in patients with MK compared with 8/28 (29%) in non-MK patients (Fischer's exact test: P ¼ 0.11).
With a median follow-up of 28.2 months in patients with complex karyotype, median OS was 7.1 in MK (n ¼ 75) and 8.7 months in non-MK (n ¼ 28) patients (log-rank test: P ¼ 0.46, Figure 1a ). The total number of cytogenetic anomalies (whether numerical or structural) only marginally affected OS when analyzed as a continuous variable (Cox model: hazard ratio ¼ 1.07 (95% confidence interval: 0.99-1.15)), and no statistically significant cutoff value could be identified.
Among the 75 MK patients, presence of monosomy 5 or 7 did not add statistically significant prognostic value, perhaps because of the small numbers considered, with median OS of 6.4 months in the 50 patients with MK involving monosomy 5 or 7, versus 9.3 months in the 25 MK patients without monosomy 5 or 7 (log-rank test: P ¼ 0.18, Figure 1b ). This is in line with the results from Patnaik et al.,
1 showing that the outcome of monosomal karyotypes is not influenced by the presence of monosomy 5 and/or 7.
The divergent results regarding the impact of monosomal karyotype among complex cytogenetics between our cohort and that of Patnaik et al.
1 can have several explanations. First, the OS of our cohort of complex karyotype patients was poorer, possibly because 117/133 (88%) of our patients had an excess of bone marrow blasts (X5%) and 75/133 (56%) had high IPSS risk compared with 57% and 23%, respectively, in the report of Patnaik et al.
1 Second, the size of the present cohort was slightly smaller than that analyzed by Patnaik et al.
1 (103 versus 127 patients, respectively). Another possibility is that treatment with AZA may reduce the negative impact of monosomal karyotype in higher risk MDS. An impact of cytogenetics on response to AZA in the AZA 001 trial has been reported, so far in abstract form, 5 but monosomal karyotypes were not analyzed in that study. Finally, our results highlight the importance to assess prognostic factors in uniformly treated populations, and the need to reevaluate these factors when novel therapeutic standards emerge. Sporadic mutations in the gene for the transcription factor CCAAT-enhancer-binding protein a (CEBPA) occur in approximately 7-9% of patients with acute myeloid leukemia (AML).
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Most of these patients harbor biallelic mutations, consisting of an N-terminal and a C-terminal mutation, which lead to loss of function of CEBPA and cause a differentiation block in the leukemic blasts.
In this study, we describe a family with AML revealing a N-terminal 338delC CEBPA germline mutation (referenced to GenBank accession number Y11525, Figures 1 and 2) . The 30-year-old mother had a history of acute lymphoblastic leukemia, remaining in complete remission (CR) for more than 25 years, when she was diagnosed with AML French-AmericanBritish type M2 with normal karyotype. She was treated with two cycles of induction chemotherapy (idarubicin, cytarabine and etoposide) and one cycle of high-dose cytarabine and mitoxantrone. After 15 months of CR, a relapse of the AML with normal karyotype occurred. When tested for molecular aberrations, a 338delC CEBPA germline mutation and an additional acquired C-terminal 1085insGAA mutation were detected (the germline mutation was verified by additional analyses of buccal mucosa). Both mutations were also present in samples from the initial diagnosis of AML, which were obtained within a prospective clinical trial. The patient's parents and her sister were tested negative for CEBPA germline mutations, and the family history showed no evidence of an inherited predisposition to hematological cancer (Figure 1) . The patient was treated with chemotherapy (fludarabine and cytarabine) and achieved a second CR. Subsequently, she received an allogeneic hematopoietic stem cell transplantation from a matched unrelated donor (10 out of 10 human leukocyte antigens loci matched; intermediate resolution DNA typing for human leukocyte antigens-A, -B and -Cw, and high-resolution DNA typing for DRB1 and DQB1). Due to intense pre-treatment and treatmentrelated congestive heart failure, a dose-reduced conditioning regimen was chosen consisting of 120 mg/m 2 fludarabine (given on 3 consecutive days) and 8 Gy total body irradiation (divided in 4 fractions over 2 days). Acute graft-versus-host disease prophylaxis consisted of anti-thymocyte globuline, cyclosporine A and a short course of methotrexate. Unfortunately, the patient died from unexpected sudden cardiac death 18 months after transplant. At that time, the patient was in continuous CR with complete donor chimerism of hematopoietic cells and no signs of graft-versus-host disease. Figure 2 Schematic representation of the wild-type CCAAT-enhancerbinding protein a (CEBPA) and the projected mutant forms in the mother and daughter as described. Both patients had a germline mutation in the 5 0 region of the coding sequence, which results in an N-terminal mutant of CEBPA. N-terminal mutants have been described to exert dominant negative activity over wild-type CEBPA.
1 Both patients also harbor a C-terminal mutation that presumably results in altered heterodimerization and DNA binding of the mutant protein.
Interestingly, the C-terminal mutants were different but very similar in the leukemic cells from the mother and those from the daughter.
